Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 14.3 USD 0.7% Market Closed
Market Cap: 989m USD
Have any thoughts about
Zymeworks Inc?
Write Note

Zymeworks Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zymeworks Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Zymeworks Inc
NASDAQ:ZYME
Research & Development
-$123.1m
CAGR 3-Years
13%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%
No Stocks Found

Zymeworks Inc
Glance View

Market Cap
1B USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
18.33 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Zymeworks Inc's Research & Development?
Research & Development
-123.1m USD

Based on the financial report for Sep 30, 2024, Zymeworks Inc's Research & Development amounts to -123.1m USD.

What is Zymeworks Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-8%

Over the last year, the Research & Development growth was 28%. The average annual Research & Development growth rates for Zymeworks Inc have been 13% over the past three years , -8% over the past five years .

Back to Top